Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial

By afschroeder • May 17, 2026

Elbuluk N, Armstrong AW, Vender R, Bhutani T, Green L, Ferris LK, Laquer V, Moore A, Weisman J, Zhang W, Winkelman W, Gooderham MJ. Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial. Dermatol Ther (Heidelb). 2026 May 16. doi: 10.1007/s13555-026-01738-6. Epub ahead of print. PMID: 42143206.

Tags: Dermatology, DLQI, Oral therapy, PASI, patient-reported outcomes, plaque psoriasis, psoriasis, Publications, Skin clearance, TYK2 inhibitor, Zasocitinib

Tralokinumab Versus Dupilumab for the Treatment of Atopic Dermatitis with Moderate-to-Severe Hand Involvement: A Matching-Adjusted Indirect Comparison

Armstrong A, Kircik L, Metelitsa A, Warren RB, Rodriguez A, Volc S, Issa N, Chovatiya R, von Eyben R, Festini T, Johansen P, Ehst B.[...]

Low-Dose Oral Minoxidil Use for Pediatric Hair Disorders: An International Consensus Statement

Akiska YM, Fu J, Castelo-Soccio L, Mathes E, Mirmirani P, Jamerson T, Sibbald C; and The Pediatric Low-Dose Oral Minoxidil Consensus Expert Group; Spagnol Abraham[...]

Robustness of Network Meta-Analysis in Chronic Plaque Psoriasis-Reply

Armstrong AW, Nong Y, Merola JF. Robustness of Network Meta-Analysis in Chronic Plaque Psoriasis-Reply. JAMA Dermatol. 2026 Sep 23. doi: 10.1001/jamadermatol.2026.3645. Epub ahead of print.[...]